GlassScriptPhysician profile
Daniela S Cavallaro
NPI 1336692011
$6,039.79
in general payments reported to CMS, 2019-2025
22 companies · $3,438 in 2025
The $3,438 reported for 2025 was more than what 97% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $558 · 2022: $836 · 2023: $1,055 · 2024: $153 · 2025: $3,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $2,500 · Food and Beverage: $1,198 · Travel and Lodging: $871 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $2,500.00 |
| Food and Beverage | $1,198.34 |
| Travel and Lodging | $871.16 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $3,371.16 | 2025 | |
| Janssen Biotech, INC. | $569.60 | 2021-2023 | Stelara, Remicade, Simponi |
| Abbvie INC. | $559.38 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $297.77 | 2021-2023 | Gattex |
| E.R. Squibb & Sons, L.L.C. | $207.95 | 2021-2022 | |
| Celgene Corporation | $201.22 | 2021-2023 | Zeposia |
| Abbott Laboratories | $139.47 | 2023-2024 | Freestyle Libre 3, Octrode |
| Pfizer INC. | $125.99 | 2021-2023 | |
| Janssen Scientific Affairs, LLC | $117.82 | 2022 | |
| Daiichi Sankyo INC. | $105.25 | 2021-2023 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.16 | 2022-2023 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $48.73 | 2024 | |
| Evoke Pharma, INC. | $32.54 | 2021 | |
| Corcept Therapeutics | $31.14 | 2024-2025 | Korlym |
| Qol Medical, LLC | $28.28 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $27.89 | 2022 | |
| Csl Behring | $19.20 | 2025 | Kcentra |
| Lilly USA, LLC | $18.63 | 2024 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $16.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.72 | 2024 | |
| Mallinckrodt Hospital Products INC. | $15.46 | 2023 | Terlivaz |
| Rhythm Pharmaceuticals, INC. | $15.44 | 2025 | Imcivree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Cavallaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.